ClinicaliQ Trial Snapshot
- Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients — Recruiting • Phase I / Phase II • NCT05876312.
- ADX-038, a new drug for rare blood disorder PNH, was tested for safety and effectiveness in healthy people and patients.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The first-in-human Phase 1/Phase 2a study described herein will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in both healthy participants (HP) and in patients with paroxysmal nocturnal hemoglobinuria (PNH). Conditions: Paroxysmal Nocturnal Hemoglobinuria (PNH) Interventions: ADX-038, Placebo Lead Sponsor: ADARx Pharmaceuticals, Inc. Planned Enrollment: 50 participants